PMID- 32015495
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20210202
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Feb 3
TI  - Cell-mediated immune response and protective efficacy of porcine reproductive and 
      respiratory syndrome virus modified-live vaccines against co-challenge with 
      PRRSV-1 and PRRSV-2.
PG  - 1649
LID - 10.1038/s41598-020-58626-y [doi]
LID - 1649
AB  - Cell-mediated immunity (CMI), IL-10, and the protective efficacy of modified-live 
      porcine reproductive and respiratory syndrome virus (PRRSV) vaccines (MLV) 
      against co-challenge with PRRSV-1 and PRRSV-2 (HP-PRRSV) were investigated. 
      Seventy, PRRSV-free, 3-week old, pigs were allocated into 7 groups. Six groups 
      were intramuscularly vaccinated with MLV, including Porcilis (PRRSV-1 MLV, MSD 
      Animal Health, The Netherlands), Amervac (PRRSV-1 MLV, Laboratorios Hipra, 
      Spain), Fostera (PRRSV-2 MLV, Zoetis, USA), Ingelvac PRRS MLV and Ingelvac PRRS 
      ATP (PRRSV-2, Boehringer Ingelheim, USA), and Prime Pac PRRS (PRRSV-2 MLV, MSD 
      Animal Health, The Netherlands). Unvaccinated pigs were left as control. 
      Lymphocyte proliferative response, IL-10 and IFN-gamma production were determined. At 
      35 days post-vaccination (DPV), all pigs were inoculated intranasally with 2 ml 
      of each PRRSV-1 (10(5.4) TCID(50)/ml) and PRRSV-2 (10(5.2) TCID(50)/ml, 
      HP-PRRSV). Following challenge, sera were quantitatively assayed for PRRSV RNA. 
      Pigs were necropsied at 7 days post-challenge. Viremia, macro- and microscopic 
      lung lesion together with PRRSV antigen presence were evaluated in lung tissues. 
      The results demonstrated that, regardless of vaccine genotype, CMI induced by all 
      MLVs was relatively slow. Increased production of IL-10 in all vaccinated groups 
      was observed at 7 and 14 DPV. Pigs in Amervac, Ingelvac MLV and Ingelvac ATP 
      groups had significantly higher levels of IL-10 compared to Porcilis, Fostera and 
      Prime Pac groups at 7 and 14 DPV. Following challenge, regardless to vaccine 
      genotype, vaccinated pigs had significantly lower lung lesion scores and PRRSV 
      antigens than those in the control group. Both PRRSV-1 and PRRSV-2 RNA were 
      significantly reduced. Prime Pac pigs had lowest PRRSV-1 and PRRSV-2 RNA in 
      serum, and micro- and macroscopic lung lesion scores (p < 0.05) compared to other 
      vaccinated groups. In conclusion, PRRSV MLVs, regardless of vaccine genotype, can 
      reduce viremia and lung lesions following co-challenge with PRRSV-1 and PRRSV-2 
      (HP-PRRSV). The main difference between PRRSV MLV is the production of IL-10 
      following vaccination.
FAU - Madapong, Adthakorn
AU  - Madapong A
AD  - Department of Veterinary Microbiology, Faculty of Veterinary Science, 
      Chulalongkorn University, Bangkok, Thailand.
FAU - Saeng-Chuto, Kepalee
AU  - Saeng-Chuto K
AD  - Department of Veterinary Microbiology, Faculty of Veterinary Science, 
      Chulalongkorn University, Bangkok, Thailand.
FAU - Boonsoongnern, Alongkot
AU  - Boonsoongnern A
AD  - Department of Farm Resources and Production Medicine, Faculty of Veterinary 
      Medicine Kamphaeng Saen Campus, Kasetsart University, Nakon Pathom, Thailand.
FAU - Tantituvanont, Angkana
AU  - Tantituvanont A
AD  - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical 
      Sciences, Chulalongkorn University, Bangkok, Thailand.
FAU - Nilubol, Dachrit
AU  - Nilubol D
AD  - Department of Veterinary Microbiology, Faculty of Veterinary Science, 
      Chulalongkorn University, Bangkok, Thailand. dachrit@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200203
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (RNA, Viral)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Viral Vaccines)
RN  - 130068-27-8 (Interleukin-10)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Immunity, Cellular
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-10/biosynthesis
MH  - Lung/immunology/pathology/virology
MH  - Lymphocyte Activation
MH  - Porcine Reproductive and Respiratory Syndrome/*immunology/*prevention & 
      control/virology
MH  - Porcine respiratory and reproductive syndrome 
      virus/classification/genetics/*immunology
MH  - RNA, Viral/blood/genetics
MH  - Sus scrofa
MH  - Swine
MH  - Vaccines, Attenuated/immunology/pharmacology
MH  - Viral Vaccines/immunology/*pharmacology
PMC - PMC6997162
COIS- The authors declare no competing interests.
EDAT- 2020/02/06 06:00
MHDA- 2020/11/18 06:00
PMCR- 2020/02/03
CRDT- 2020/02/05 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/02/05 06:00 [entrez]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/02/03 00:00 [pmc-release]
AID - 10.1038/s41598-020-58626-y [pii]
AID - 58626 [pii]
AID - 10.1038/s41598-020-58626-y [doi]
PST - epublish
SO  - Sci Rep. 2020 Feb 3;10(1):1649. doi: 10.1038/s41598-020-58626-y.